Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
76.14 USD | -1.16% |
|
+9.84% | +148.11% |
Jul. 10 | Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating | MT |
Jul. 09 | Guggenheim Adjusts Price Target on Insmed to $95 From $70, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+148.11% | 12.42B | |
+21.43% | 127B | |
+24.81% | 117B | |
+26.17% | 27.77B | |
-19.04% | 20.44B | |
-14.45% | 16.62B | |
-12.41% | 15.92B | |
-46.65% | 14.94B | |
+12.49% | 14.74B | |
+57.15% | 14.38B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Truist Securities Adjusts Price Target on Insmed to $68 From $48 After Positive ASPEN Results, Maintains Buy Rating